Company Overview: Matinas BioPharma

Industry News

28 May

Matinas BioPharma to Present at the LD Micro Invitational on June 2, 2015

Presentation With Live Webcast at 3:00 p.m. PDT / 6:00 p.m. EDT Matinas BioPharma Holdings, Inc.(“Matinas BioPharma” or the “Company”) (MTNB), a clinical-stage biopharmaceutical company principally focused on the development of targeted therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the LD...

Read more

26 May

Matinas BioPharma to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015

– Presentation With Audio Webcast at 11:30 a.m. EDT – Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) (MTNB), a clinical-stage biopharmaceutical company principally focused on the development of lipid-based prescription therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the Fourth Annual...

Read more

16 Apr

MTNB: Matinas’ Pipeline Is Ready To Shine

    By Jason Napodano, CFA Twitter: @JNapodano Matinas (MTNB) announced the establishment of a lipid-based, anti-infective platform with the acquisition of Aquarius BioTechnologies, Inc. This was the Bioral™ technology previously owned by BioDelivery Sciences International (BDSI) from 2002 to 2009. BioDelivery was unable to move forward with the technology because...

Read more

4 Mar

Matinas BioPharma to Present at the 27th Annual ROTH Conference on March 11, 2015

Live Presentation With Audio Webcast on Wednesday, March 11th at 11:30 a.m. Pacific Time / 2:30 p.m. Eastern Time Matinas BioPharma Holdings, Inc. (Matinas BioPharma or the Company) (MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of fungal and...

Read more

23 Feb

SeeThruEquity Issues Company Update on Matinas BioPharma Holdings Highlighting Aquarius Biotechnologies Acquisition

SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company update on Matinas BioPharma Holdings, Inc. (MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address